EHS
EHS

Norfloxacin ineffective for cirrhosis survival, but beneficial in ascites

Results of a randomized control trial of patients with advanced cirrhosis without recent fluoroquinolone therapy showed that norfloxacin did not reduce 6-month mortality but did appear to increase survival among patients with low ascites fluid protein concentration.
“Of note, the beneficial effect of norfloxacin on the risk of any infection and Gram-negative bacterial infections, was maintained, and even extended to Gram-positive bacterial infections, during the double-blind post-treatment period,” Richard Moreau, MD, from the Assistance Publique – Hôpitaux de Paris,

Source link

EHS
Back to top button